Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz)
Klinisch orientierter Schwerpunkt / Johannes Gutenberg-Universität Mainz
Mahmoudpour, Seyed Hamidreza; Bandapalli, Obul Reddy; da Silva Filho, Miguel Inacio et al.
Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patientsBMC CANCER. Bd. 18. 2018
Kindler, Thomas
CHIPing out PPM1D-mutant hematopoiesisBLOOD. Bd. 132. H. 11. 2018 S. 1087-1088
Moehler, M.; Maderer, A.; Thuss-Patience, P. et al.
Cisplatin/5-fluorouracil plus /- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker programANNALS OF ONCOLOGY. Bd. 29. 2018
Panova-Noeva, M.; Schulz, A.; Arnold, N. et al.
Coagulation and inflammation in long-term cancer survivors: results from the adult populationJOURNAL OF THROMBOSIS AND HAEMOSTASIS. Bd. 16. H. 4. 2018 S. 699-708
Dahlhaus, Anne; Siebenhofer, Andrea; Guethlin, Corina et al.
Colorectal cancer stage at diagnosis in migrants and non-migrants: a cross-sectional analysis of the KoMigra Study in GermanyZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 56. H. 12. 2018 S. 1499-1506
Bartlett, John M. S.; Bayani, Jane; Kornaga, Elizabeth et al.
Comparative survival analysis of multiparametric tests in the TEAM pathology study: What to do when molecular tests disagree?CANCER RESEARCH. Bd. 78. H. 4. 2018
Korfei, Martina; Stelmaszek, Daniel; MacKenzie, BreAnne et al.
Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosisPLOS ONE. Bd. 13. H. 11. 2018
Jurczak, Wojciech; Ramanathan, Sundra; Giri, Pratyush et al.
Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphomaLEUKEMIA & LYMPHOMA. Bd. 59. H. 3. 2018 S. 670-678
Stintzing, S.; Lenz, H. -J.; Neureiter, D. et al.
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and 1st-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE-3 (AIO KRK-0306) trialONCOLOGY RESEARCH AND TREATMENT. Bd. 41. 2018 S. 8-9
Bayani, Jane; Kornaga, Elizabeth N.; Crozier, Cheryl et al.
Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancersCANCER RESEARCH. Bd. 78. H. 4. 2018